The FDA has posted Class II recalls covering sildenafil citrate USP and tadalafil USP active pharmaceutical ingredient produced by Shoolin Pharma Chem LLP and supplied in one-kilogram and half-kilogram bags labelled for prescription compounding only. The stated reason is current good manufacturing practice deviations found during an FDA inspection, and the recall status is recorded as ongoing.

What this is, and is not, matters. A Class II recall means the product may cause temporary or medically reversible harm, with a remote probability of serious consequences - it sits below the Class I designation used for products likely to cause serious harm or death. This is a manufacturing quality action against bulk raw material destined for compounding pharmacies, not a safety finding about sildenafil or tadalafil as drugs, and not a recall of any finished branded or generic tablet. No patient taking a licensed sildenafil or tadalafil product is affected by this notice.

The Indian angle is direct: the manufacturer is an Indian API producer, and Indian facilities supply a large share of the world's generic active ingredients. CDSCO has issued no corresponding action that this notice reflects, and the recall applies to material shipped into the American compounding supply chain. It is worth knowing about mainly because patients read headlines about recalls of drugs they take, and the accurate answer to that question here is that finished products are not involved.

Reassure patients on licensed sildenafil or tadalafil tablets - no finished product is recalled
Note the distinction between an active ingredient recall for manufacturing deviations and a drug safety finding; this is the former
Class II means possible temporary or reversible harm, not the serious-harm category
Where a patient uses a compounded preparation obtained abroad, that is the only route by which this material would reach them
Do not extrapolate to an assessment of the manufacturer's other products; the notice covers these consignments

Why it matters

Patients will hear 'sildenafil recall' and assume their tablets are affected, and they are not.

Don't overread it

A current good manufacturing practice deviation found at inspection is an administrative and quality finding, not evidence that any patient was harmed.